lower schreef op 7 november 2016 11:43:
De licence fees lopen door tot "closing of the acquisition".
Wat denken jullie?
Stel de FDA zou Phase3 niet als noodzakelijk zien en dit wordt bekend voor de "closing of the acquisition".
Zou de "profylactic milestone" dan moeten worden uitgekeerd?
Pharming Reports on Financial Results for the First Nine Monthsof 2016
www.pharming.com/wp-content/uploads/2...p3
On 9 August 2016, the Company announced that it has entered into a definitive agreement to acquire all North American commercialization rights to its own product RUCONEST® (recombinant human C1 esterase inhibitor), including all rights in the US, Mexico and Canada, from Valeant
Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX).
Under the terms of the agreement, Pharming will pay Valeant an upfront fee of US$60 million upon Closing, which is expected during the fourth quarter this year. In addition, over the coming years the Company will make one-time-only
self-funding(meaning that no external financial resources should be necessary to finance them) payments to Valeant on the achievement of a small number of specific sales milestones events, totalling a maximum of US$65 million.
The specific details of these additional transaction terms are not disclosed for commercial reasons. The transaction is subject to Pharming
obtaining adequate financing over the coming weeks.
p7
It should be noted that the remaining license fee income related to Salix and Santarus which has not been released by the date of Closing of the acquisition will be released immediately and deducted from the acquisition cost in determining the level of intangible asset acquired.
This is expected to be €4.7 million.